Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at SITC Annual Meeting
PALO ALTO, CA, November 9, 2021 / Business Wire / -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that the Company will present a scientific poster at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021) being held November 10-14, 2021, in Washington, D.C., USA.
The poster will feature key preclinical data demonstrating the therapeutic potential of anti-LAIR1 antagonistic antibodies as immune checkpoint inhibitor therapy for solid tumors. LAIR1 (Leukocyte Associated Immunoglobulin-like Receptor 1) is an immune inhibitory transmembrane glycoprotein expressed on lymphocytes and myeloid cells and is activated by collagen and other ligands. Collagen is highly abundant in the stroma of many solid tumor types and thought to contribute to immune suppression. The data being presented suggest that LAIR1 blockade could potentially reverse collagen-mediated myeloid cell tolerogenic phenotype and T-cell suppression, thereby promoting a pro-inflammatory solid tumor microenvironment.
Poster Presentation:
- Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells